Alchemia Limited is a biotechnology company engaged in developing human therapeutics based on its drug discovery and synthesis technologies. The Company's business segments include Fondaparinux and HyACT. The Fondaparinux is an injectable anticoagulant drug, which is used in the prevention and treatment of deep vein thrombosis and pulmonary embolism. The Fondaparinux is mainly used after surgery, such as in knee and hip replacements. The HyACT is a platform technology that uses the non-toxic and naturally occurring carbohydrate, hyaluronic acid (HA) as a targeting vehicle for a range of approved anti-cancer therapeutics. In addition, it is developing HA-Irinotecan, which is in Phase III clinical trials for the treatment of metastatic colorectal cancer (mCRC) and is in Phase II clinical trials for the treatment of small cell lung cancer (SCLC). HA-Irinotecan is also being tested in combination with therapeutic antibody, Erbitux (cetuximab) in second-line mCRC patients (CHIME trail).